Lv21
120 积分 2022-09-19 加入
The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design
4小时前
已完结
Advances in Development of Selective Antitumor Inhibitors That Target PARP-1
4小时前
已完结
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
4小时前
已完结
Recent PARP Inhibitor Advancements in Cancer Therapy: A Review
4小时前
待确认
Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)
4小时前
已完结
Linker Design for The Antibody Drug Conjugates: A Comprehensive Review
6天前
已完结
Design, Synthesis, and Biological Evaluation of WEE1 degraders via HSP90-mediated Targeting Chimeras for Target Therapy of Acute Myeloid Leukemia
17天前
已完结
Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates
1个月前
已完结
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor
1个月前
已完结
Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models
1个月前
已完结
皖公网安备34019202002308
